SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that the clinical role of hyperthermia was the focus at the annual European Society for Hyperthermic Oncology (ESHO) Meeting, which was held in Aarhus, Denmark, May 26-28, 2011. The 27th annual ESHO meeting was held in conjunction with the 20th annual European BSD Users Meeting. The object of the ESHO meeting was to review recent developments that will increase the clinical role of hyperthermia.
The scientific program of ESHO 2011 covered the major clinical, physical and biological developments within hyperthermia. Presentations at the conference included clinical studies on the use of hyperthermia in combination with radiotherapy and/or chemotherapy to treat the following tumors: rectal cancer, soft tissue sarcoma, esophagus cancer, nasal and paranasal sinus cancer, head and neck tumors, pancreatic cancer, pediatric cancers, recurrent breast cancer and cervical cancer. There were also a number of presentations on the use of thermotherapy with nanotechnology.
Dr. Udo S. Gaipl, Head of Radiation Immunobiology, University Hospital Erlangen, reviewed the data on the biological mechanisms that occur with hyperthermia. Dr. Gaipl stated that data have shown that hyperthermia directly kills cancer cells, stops the proliferation of cancer cells, as well as increases the effectiveness of other cancer therapies. Dr. Gaipl also reported that data have shown that hyperthermia can significantly stimulate the immune system, which increases tumor damage.
ESHO was established to promote research in physics, engineering, biological and clinical sciences relating to the use of hyperthermia in cancer therapy. The aim of the society is to increase collaboration between hyperthermia centers in order to design additional prospective studies to better define the role of hyperthermia.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for many years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia), while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. The BSD-2000 is restricted to investigational use in the U.S. BSD has applied for a Humanitarian Device Exemption (HDE) approval for its BSD-2000 Hyperthermia System and this submission is currently under review by the FDA. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
BSD Medical Corporation
Dennis Gauger, 801-972-5555
KEYWORDS: United States Europe North America Denmark Utah
INDUSTRY KEYWORDS: Health Biotechnology Medical Devices Oncology General Health